AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$BHVN

Biohaven Ltd.

Price · $BHVNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $BHVN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $BHVN in the last 30 days.

Top stories · $BHVNMore →
MAY 12·Simply Wall StreetLow

Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration

Biohaven (BHVN) is under scrutiny after its Q1 results and a new shelf registration. Despite a reduced net loss, its share price has fallen significantly, leading to questions about its valuation. The company's Price-to-Book ratio of 10.6x is below peers but well above the biotech sector, indicating that its current market value relies heavily on expectations for its extensive pipeline rather than current profitability.

MAY 12·Investing.com

H.C. Wainwright reiterates Biohaven stock rating ahead of trial

H.C. Wainwright has reiterated a Neutral rating and $10.00 price target for Biohaven Pharma (BHVN) due to uncertainty surrounding its pipeline, as the stock has declined 56% over the past year. The firm remains cautious ahead of the upcoming second-half 2026 pivotal readout for opakalim in FOS, a key catalyst. Biohaven faces increased pressure for clinical success as it is burning through cash, and competitors' recent successes in similar mechanisms raise the bar for efficacy and tolerability differentiation.

MAY 4·StreetInsider

Biohaven Pharma (BHVN) files mixed shelf

Biohaven Pharma (BHVN) has filed a mixed shelf offering that includes common shares, preferred shares, depositary shares, debt securities, warrants, rights, purchase contracts, and units. The stock is currently priced at $10.14, up 5.30%, with an overall analyst rating of SELL. This filing provides the company with flexibility to raise capital through various securities in the future.

News on $BHVN

All news →